ArticleTranslational oncology2026
Distinct genomic landscape of non-small cell lung cancer in Bangladeshi patients: Implications for precision oncology in a resource-limited setting.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is a genetically heterogeneous disease with clinically actionable mutations. Analysis of circulating tumor DNA (ctDNA) in plasma using next-generation sequencing (NGS) provides a minimally invasive method for profiling tumor-associated genomic alterations. However, the ctDNA mutational landscapes of Bangladeshi NSCLC patients remain scarce.
methodsWe enrolled 106 patients with NSCLC and performed targeted NGS of ctDNA, covering a panel of key genes, including EGFR, TP53, KRAS, ERBB2, BRAF, MET, NRAS, PIK3CA, ALK,MAP2K1, and ROS1.
resultsMutations were detected in 85.8% of patients, with TP53, EGFR, and KRAS being the most frequently altered genes. Single gene mutations predominated in females, whereas males exhibited higher rates of multiple concurrent mutations, and KRAS mutations were significantly associated with males. Pathogenic variant c.2155G>A of EGFR was most frequent in the 50-70-year group. The TP53 pathogenic variant c.580G>A was found in 14 patients, and 11 patients showed pathogenic variant c.35G>A in KRAS. The highest number of pathogenic mutations was found in EGFR, followed by TP53, KRAS, ERBB2, BRAF, NRAS, MET, and PIK3CA. No mutation was found in ROS1. Prevalence of EGFR mutations aligns with that in other Asian populations, while frequencies of TP53 and KRAS mutations are consistent with global datasets.
conclusionThe high prevalence of EGFR and TP53 alterations underscores the importance of molecular testing to guide targeted therapy. This is the first comprehensive ctDNA-based genomic landscape for NSCLC in Bangladesh and supports the integration of liquid biopsy into precision oncology strategies in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.